Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

PBLA-PR-definitive-agreement-2-22-22

.pdf

Download PDF • 209KB

Featured Posts

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Group Represents Solvotrin to License Their Novel ActiveIronTM Product Portfolio

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Sage Represents Mateon Therapeutics - Leadership in Novel Vascular Targeted Therapy

Recent Posts

Eurofins Discovery Announces Aquisition of Sage Client Discovery BioMed

Kinnov Therapeutics Completes Successful Phase 2 study for Alcohol Use Disorder

Hatchtech appoints Sage Group to divest its FDA-approved Xeglyze® for head lice treatment

Sage Advises Cancer Prevention Pharmaceuticals on Merger with Panbela Therapeutics

Product Opportunity for Rare Hematological Disease - KDFX for Iron Overload Disorder from Dispersol

Opportunity in Cellular Immunotherapy with oNKord Unmodified Natural Killer Cells from Glycostem

SalivaPod - Novel Saliva Sample Collection for a New Era of Diagnostics

Novel Gene Therapy Treatment for Head and Neck Cancer with Impressive Phase III Results in China

The Sage Group Invites You to a Webinar by Axiom Space on November 30, 2021at 11 AM Eastern Time

The Sage Group Advises Cancer Prevention Pharmaceuticals on Transaction for Orphan Drug

Archive

Search By Tags

Follow Us